细胞培养条件对马里巴韦抗巨细胞病毒活性的影响。
Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.
作者信息
Chou Sunwen, Van Wechel Laura C, Marousek Gail I
机构信息
Medical and Research Services, VA Medical Center and Oregon Health & Scince University, Portland, OR 97239, USA.
出版信息
Antimicrob Agents Chemother. 2006 Jul;50(7):2557-9. doi: 10.1128/AAC.00207-06.
Abstract
The cytomegalovirus UL97 kinase inhibitor maribavir suppressed viral growth more effectively in lung fibroblasts than in skin fibroblasts, and some cellular kinase inhibitors enhanced its antiviral activity. These effects influence the phenotypic assay of drug susceptibility and suggest the possibility of therapeutically useful combinations of maribavir and cellular kinase inhibitors.
摘要
巨细胞病毒UL97激酶抑制剂马里巴韦在肺成纤维细胞中比在皮肤成纤维细胞中更有效地抑制病毒生长，并且一些细胞激酶抑制剂增强了其抗病毒活性。这些效应影响药物敏感性的表型测定，并提示马里巴韦与细胞激酶抑制剂进行治疗性联合应用的可能性。
相似文献
1
Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.细胞培养条件对马里巴韦抗巨细胞病毒活性的影响。
Antimicrob Agents Chemother. 2006 Jul;50(7):2557-9. doi: 10.1128/AAC.00207-06.
2
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.巨细胞病毒UL97激酶突变导致对马立巴韦耐药。
J Infect Dis. 2007 Jul 1;196(1):91-4. doi: 10.1086/518514. Epub 2007 May 17.
3
Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.马里巴韦可拮抗更昔洛韦对人巨细胞病毒的抗病毒作用。
Antimicrob Agents Chemother. 2006 Oct;50(10):3470-2. doi: 10.1128/AAC.00577-06.
4
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.人巨细胞病毒 UL27 基因中赋予对马立巴韦耐药性的突变。
J Virol. 2004 Jul;78(13):7124-30. doi: 10.1128/JVI.78.13.7124-7130.2004.
5
Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.巨细胞病毒 pUL97 激酶同工型的差异特性影响病毒复制和马拉维若的敏感性。
J Virol. 2014 May;88(9):4776-85. doi: 10.1128/JVI.00192-14. Epub 2014 Feb 12.
6
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.体外和体内药物暴露后检测到的巨细胞病毒 UL97 激酶 ATP 结合区域突变对马拉韦罗敏感性的影响。
Antiviral Res. 2012 Aug;95(2):88-92. doi: 10.1016/j.antiviral.2012.05.013. Epub 2012 Jun 1.
7
Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.人巨细胞病毒UL97基因在嵌合豚鼠巨细胞病毒（GPCMV）中的表达产生了对更昔洛韦和马立巴韦敏感性增加的活病毒。
Antiviral Res. 2008 Jun;78(3):250-9. doi: 10.1016/j.antiviral.2008.01.008. Epub 2008 Feb 14.
8
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.多种巨细胞病毒UL27突变可适应在马里巴韦作用下病毒UL97激酶活性的丧失。
Antimicrob Agents Chemother. 2009 Jan;53(1):81-5. doi: 10.1128/AAC.01177-08. Epub 2008 Nov 3.
9
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.更昔洛韦和马里巴韦时代的巨细胞病毒UL97突变
Rev Med Virol. 2008 Jul-Aug;18(4):233-46. doi: 10.1002/rmv.574.
10
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.人巨细胞病毒对苯并咪唑L-核糖核苷马里巴韦的耐药性定位到UL27。
J Virol. 2003 Nov;77(21):11499-506. doi: 10.1128/jvi.77.21.11499-11506.2003.
引用本文的文献
1
Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target.了解巨细胞病毒周期蛋白依赖性激酶同源物 pUL97 作为一个多方面的调节剂和抗病毒药物靶点。
Cells. 2024 Aug 13;13(16):1338. doi: 10.3390/cells13161338.
2
New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.实体器官移植患者巨细胞病毒管理的新见解：耐药/难治性疾病的预防、治疗与管理
Infect Dis Ther. 2023 Feb;12(2):333-342. doi: 10.1007/s40121-022-00746-1. Epub 2022 Dec 30.
3
The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides.哌啶-4-甲酰胺的合成及抗巨细胞病毒活性。
Viruses. 2022 Jan 25;14(2):234. doi: 10.3390/v14020234.
4
Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses.抗病毒药物的现状与策略：第一部分：DNA病毒和逆转录病毒
Adv Antivir Drug Des. 2007;5:1-58. doi: 10.1016/S1075-8593(06)05001-5. Epub 2007 Sep 2.
5
The Cytomegalovirus Protein Kinase pUL97:Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting.巨细胞病毒蛋白激酶pUL97：宿主相互作用、调控机制及抗病毒药物靶向作用
Microorganisms. 2020 Apr 4;8(4):515. doi: 10.3390/microorganisms8040515.
6
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.从更昔洛韦和膦甲酸钠转移：CMV 治疗的进展。
Curr Hematol Malig Rep. 2020 Apr;15(2):90-102. doi: 10.1007/s11899-020-00557-6.
7
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.巨细胞病毒抗病毒药物耐药性的基因诊断进展。
Antiviral Res. 2020 Apr;176:104711. doi: 10.1016/j.antiviral.2020.104711. Epub 2020 Jan 12.
8
Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data.通过激酶抑制剂筛选数据的机器学习分析鉴定靶向 MAP4K4 的抗人巨细胞病毒先导化合物。
PLoS One. 2018 Jul 26;13(7):e0201321. doi: 10.1371/journal.pone.0201321. eCollection 2018.
9
Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.马拉韦罗与其他抗人巨细胞病毒药物联合的抗病毒活性。
Antiviral Res. 2018 Sep;157:128-133. doi: 10.1016/j.antiviral.2018.07.013. Epub 2018 Jul 21.
10
The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.青蒿琥酯是一种有效的人巨细胞病毒复制抑制剂。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00288-18. Print 2018 Jul.
本文引用的文献
1
Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.通过使用包含报告基因的重组病毒对巨细胞病毒耐药性突变进行表型分析。
Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5. doi: 10.1128/AAC.49.7.2710-2715.2005.
2
The pleiotropic effects of mTor inhibitors.mTor抑制剂的多效性作用。
J Nephrol. 2004 Nov-Dec;17(6):762-8.
3
Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.细胞周期蛋白依赖性激酶活性在早期对于人巨细胞病毒UL122 - 123和UL37立即早期转录本的准确加工和积累是必需的，而在后期对于病毒产生是必需的。
J Virol. 2004 Oct;78(20):11219-32. doi: 10.1128/JVI.78.20.11219-11232.2004.
4
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase.人巨细胞病毒感染诱导雷帕霉素不敏感的mTOR激酶下游效应器磷酸化。
J Virol. 2004 Oct;78(20):11030-9. doi: 10.1128/JVI.78.20.11030-11039.2004.
5
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.苯并咪唑D-和L-核糖核苷对疱疹病毒的体外活性。
Antimicrob Agents Chemother. 2003 Jul;47(7):2186-92. doi: 10.1128/AAC.47.7.2186-2192.2003.
6
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.一项I期剂量递增试验，评估1263W94在无症状人巨细胞病毒（HCMV）脱落的人类免疫缺陷病毒感染男性中的药代动力学、抗HCMV活性和安全性。
Antimicrob Agents Chemother. 2002 Sep;46(9):2969-76. doi: 10.1128/AAC.46.9.2969-2976.2002.
7
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.1263W94（一种具有独特作用模式的苯并咪唑L-核糖苷）对人巨细胞病毒复制具有强效且选择性的抑制作用。
Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72. doi: 10.1128/AAC.46.8.2365-2372.2002.
8
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.人巨细胞病毒上调磷脂酰肌醇3激酶（PI3-K）信号通路：抑制PI3-K活性可抑制病毒复制及病毒诱导的信号传导。
J Virol. 2001 Jul;75(13):6022-32. doi: 10.1128/JVI.75.13.6022-6032.2001.
9
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.实验性免疫抑制剂来氟米特在体外和体内对巨细胞病毒的抑制作用。
Intervirology. 1999;42(5-6):412-8. doi: 10.1159/000053979.
10
Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.抑制细胞周期蛋白依赖性激酶2（Cdk2）的活性可阻断人巨细胞病毒的复制。
Virology. 1997 May 12;231(2):239-47. doi: 10.1006/viro.1997.8489.
Zotero 插件